<DOC>
	<DOC>NCT02619617</DOC>
	<brief_summary>The purpose of this study to determine if SOM230 is safe and effective for the treament of cluster headache.</brief_summary>
	<brief_title>Safety and Efficacy Study of SOM230 s.c. in Cluster Headache</brief_title>
	<detailed_description>The purpose of this non-confirmatory study is to determine if SOM230 has adequate efficacy and safety to warrant further clinical development in cluster headache (CH). This study will have two parts. Part A will be a parallel design SOM230 vs. Placebo, and following an observed signal in Part A at an interim analysis, Part B of the study will be a comparison of SOM230 to sumatriptan.</detailed_description>
	<mesh_term>Headache</mesh_term>
	<mesh_term>Cluster Headache</mesh_term>
	<mesh_term>Sumatriptan</mesh_term>
	<criteria>(Part A, and Part B) Subject is male or female age 1865 inclusive. Written informed consent must be obtained before any assessment is performed. Subjects must have established diagnosis of episodic cluster headaches (CH) or chronic CH, averaging 26 headache attacks per day each lasting at least 45 minutes without treatment, not to exceed 6 attacks per day within the last year. Able to communicate well with the investigator, to understand and comply with the requirements of the study, as well as accepting NOT to share any study information through social media during their participation in the study. Subject is able to selfinject medication subcutaneously or have the assistance of a partner on an outpatient basis. (Part A, and Part B) Subjects that have a history of greater than 6 CH attacks per day within the last year. Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during the duration of the study. History of multiple and recurring allergies or allergy to the investigational compound/compound class being used in this study. Use of other investigational drugs at the time of enrollment, or within 5 halflives of enrollment, or within 30 days, whichever is longer; or longer if required by local regulations. A history of clinically significant heart diseases, ECG abnormalities, continued use of drugs known to prolong QTc during the study conduct, or any of the following ECG abnormalities at screening or baseline: QTcF &gt; 450 msec (males) QTcF &gt; 460 msec (females) Uncontrolled diabetes as evidenced by screening HbA1c &gt; 8.0% A positive Hepatitis B surface antigen or Hepatitis C test result. Acute cholecystitis or symptomatic cholelithiasis in subjects without H/O cholecystectomy (Part B Only) History of untreated or uncontrolled hypertension, stroke, peripheral arterial disease or ischemic bowel disease. History of multiple and recurring allergies to sumatriptan.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Cluster Headache</keyword>
	<keyword>Patient Diary collection of headache pain</keyword>
	<keyword>Biomarker - saliva samples</keyword>
</DOC>